What is Driving Deals in Pharmaceuticals?

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

  • VIDEO TEXT

Dec. 19 (Bloomberg) -- Bloomberg’s Sam Fazeli discusses deals between various pharmaceutical companies and why that may mean for the market. He speaks on Bloomberg Television’s “On The Move.” (Source: Bloomberg)

Why now?

What is driving these deals?

First of all, there is a lot of stuff on the move.

We have these two deals, a lot of them have been presaged if you look at some of the news flow.

We expected astrazeneca to continue its deals.

This is but they have been talking about.

This makes a lot of sense.

This relationship they have with chris myers, it is converting itself to a pharmaceutical company much more focused on specialized tech products.

Diabetes is a much more mass- market type disease.

It fits nicely.

It fits for them and it helps them continue to build the revenue line and that private line as they contend with the numerous patent expires they have coming up.

That is the good news.

The devil is in the details.

We have to look at the numbers a little bit more in detail.

It seems like about the same sort of price that things were valued at the time when the two companies together took another out.

That is where the injectable assets come from.

Not a huge surprise, but when you look at the end of the resolution, you see that after taking a $1.7 billion charge for repayment of the assets, that is one of the key assets that they acquired.

It was a lead product.

Not a huge surprise.

I am just a bit surprised the company had expected so much so early where the rest of the market analysts were thinking it would take a while.

Talk to me about bayer.

They have told us, they are going to do small and midsized deals.

This fits.

Are they paying too much for algeta.

We don't want to go there whether it is too much too little.

It is a great deal.

The management board of alg eta have recommended it.

We will do some analysis pretty quickly.

It is a cash deal.

There is no contingency which is interesting.

Usually, some deals have contingents, value rights or some longer-term milestone.

This is just cash.

Are they going to do more?

Do you think mayor is going to do more deals?

It is not necessarily the most active company.

This is like the fifth largest deal they have done.

It is the largest pharma deal that they have been involved in since they're sharing acquisition.

Gray tabby with us.

-- right to have you with us.

Thank u so much for covering those stocks.

The pulse is coming up in 15 minutes.

Guy johnson is flying solo -- no, you are not.

You have young anna edwards with you.

Can forward to that.

This text has been automatically generated. It may not be 100% accurate.

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change